Triple
T6003657
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Emgality |
E133653
|
entity |
| Predicate | isBrandNameOf |
P40804
|
FINISHED |
| Object | galcanezumab |
E133653
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: galcanezumab | Statement: [Emgality, isBrandNameOf, galcanezumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: galcanezumab Context triple: [Emgality, isBrandNameOf, galcanezumab]
-
A.
Emgality
chosen
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
-
B.
bapineuzumab
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
-
C.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: isBrandNameOf Context triple: [Emgality, isBrandNameOf, galcanezumab]
-
A.
hasBrandName
chosen
Indicates that an entity is associated with or identified by a specific brand name.
-
B.
parentBrand
Indicates that one brand is the overarching or owning brand from which another brand is derived or subordinated.
-
C.
usedBrand
Indicates that an entity has utilized, applied, or operated a particular brand in some context.
-
D.
usesBrandCharacter
Indicates that one entity employs or features another entity’s brand character (such as a mascot or branded persona) in its materials, products, or communications.
-
E.
brandNameDerivedFrom
Indicates that the brand’s name is derived from, based on, or taken from another specified name or source.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00872444c8190bfaf1739dcec765c |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04f0f63148190826198281dce3713 |
completed | March 22, 2026, 8:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c11365741c819097a43a49dd2428c1 |
completed | March 23, 2026, 10:18 a.m. |
| PD | Predicate disambiguation | batch_69c049e3316c819087ea635fa7ee8472 |
completed | March 22, 2026, 7:58 p.m. |
Created at: March 22, 2026, 4:06 p.m.